Thrombose
.webp/jcr:content/Cardio2_cover%20(2).webp)
Articles
.svg)
2024 ESC Guidelines for the management of chronic coronary syndromes
Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium
What is PRALUENT®?
PRALUENT®: a powerful PCSK9i that ticks all the boxes1–4
PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1
Lipid management in patients with diabetes mellitus
Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Éducation
.png/jcr:content/thumbnail%20(10).png)
.png)
.png/jcr:content/image%20-%202023-09-05T164029.092.png)
.svg)
